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Several coreceptors in addition to CCR5 and CXCR4 support immunodeficiency virus entry in transfected cells, but whether
they could play a role in HIV-1 pathogenesis is uncertain. To probe whether human macrophages express potentially
functional alternative entry pathways, we analyzed cell–cell fusion and infection of primary macrophage by several SIVmac
Envs. All Envs fused with normal macrophages. One, SIVmac316, also fused efficiently with macrophages lacking CCR5.
CCR5-independent fusion was not mediated by CXCR4 and was CD4 dependent, while CCR5-mediated fusion was partly
independent of CD4. However, pseudotype virions carrying the SIVmac316 Env and HIV-1 core could not infect macrophages
through the CCR5-independent pathway, although they did infect wild-type macrophages. Thus, human macrophages
possess an alternative coreceptor pathway that mediates SIV Env fusion but does not support infection. Macrophage entry
pathways other than CCR5 and CXCR4 may have limited potential in pathogenesis given their restricted capacity for infection
despite efficient fusion. © 2001 Academic Press
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HIV-1 and SIV infection are initiated by sequential
interactions of the envelope glycoprotein (Env) with cell-
surface CD4 and a seven transmembrane-spanning
(7TM) G-protein-coupled chemokine receptor (GPCR)
(reviewed in Berger et al., 1999). Either CCR5 or CXCR4 is
used by all HIV-1 strains, and these two coreceptors are
the principal pathways used by HIV-1 to infect primary
human target cells (Zhang and Moore, 1999; Yi et al.,
1999). However, many other 7TM chemokine or orphan
receptors are used to varying degrees by smaller sub-
sets of HIV-1 in transfection-based systems, including
CCR3, CCR8, CCR2b, APJ, ChemR23, GPR1, GPR15,
STRL33, CX3CR1, and others (Doranz et al., 1996; Choe et
al., 1996; Liao et al., 1997; Deng et al., 1997; Rucker et al.,
1997; Samson et al., 1998; Edinger et al., 1998a,b; Broder
and Jones-Trower, 1999). It is uncertain whether any
coreceptors other than CCR5 and CXCR4 participate in
HIV-1 entry in vivo or in pathogenesis. Except for a few
isolates (Zhang and Moore, 1999), the secondary core-
ceptors generally support HIV-1 entry inefficiently even
when overexpressed in transfection-based systems,
which suggests that there is likely little selective advan-
tage for an isolate to use alternative entry pathways in
the presence of the efficient primary coreceptors. How-
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142ever, considerable effort is currently being directed at
developing therapeutic strategies that block CCR5- and
CXCR4-mediated entry (D’Souza et al., 2000). Thus, se-
lective pressures exerted by CCR5 and CXCR4 antago-
nism could result in the emergence of variants that utilize
alternative coreceptors if such molecules were ex-
pressed by CD4-positive human cells relevant to HIV-1
pathogenesis in a form capable of mediating viral entry.
Unlike HIV-1, most SIV strains use a number of alter-
native coreceptors very efficiently in transfection-based
systems (Farzan et al., 1997; Rucker et al., 1997; Deng et
al., 1997; Samson et al., 1998). SIV also uses CCR5 but,
except for infrequent examples, does not use CXCR4
(Broder and Jones-Trower, 1999; Owen et al., 2000). SIV
can use alternative coreceptors to infect transformed
human cell lines such as CEMX174 and U87-CD4, which
lack CCR5 but express GPR1, GPR15, or others (Farzan et
al., 1997; Kirchhoff et al., 1997). Their widespread and
efficient utilization suggests that the alternative corecep-
tors may play a role in SIV pathogenesis, although one
study reported that GPR15 utilization did not affect viral
replication in rhesus macaques infected with SIVmac
(Po¨hlmann et al., 1999). Thus, even though SIV and HIV-1
differ in their use of entry coreceptors, SIV can serve as
a probe into alternative pathways that might be ex-
pressed in functional form on human cells.
Macrophages are an important target cell for HIV-1 in
vivo. Both CCR5 and CXCR4 are expressed on macro-
phages and mediate HIV-1 infection (Yi et al., 1998, 1999;
Simmons et al., 1998). Several other potential corecep-
tors have been reported to be expressed by macro-
143ALTERNATIVE SIV CORECEPTORS ON HUMAN MACROPHAGESphages (Deng et al., 1997; Edinger et al., 1998a,b; Sam-
son et al., 1998), but entry coreceptor function requires
more than just cell-surface expression and depends on
factors such as expression level, multimerization, and
association with other molecules and/or other yet-unde-
fined cell-specific features (Rucker et al., 1997; Platt et
al., 1998; Lapham et al., 1999; Dimitrov et al., 1999). Thus,
an important question is whether macrophages express
pathways other than CCR5 and CXCR4 that could poten-
tially provide routes of entry. To test whether alternative
coreceptors are expressed in macrophages in a form
that could support immunodeficiency virus entry, we an-
alyzed cell–cell fusion mediated by SIV Env with primary
human macrophages. Since some SIV strains can enter
target cells independent of CD4 (Edinger et al., 1997;
Martin et al., 1997), we also examined the CD4 depen-
dence of fusion. Finally, to define the relationship be-
tween coreceptor-mediated fusion and infection, we an-
alyzed infection through these pathways.
RESULTS
CCR5-independent fusion with human macrophages
by SIVmac
SIVmac efficiently uses several coreceptors besides
CCR5 for fusion and infection in transfected cells. To
determine whether non-CCR5 pathways for SIVmac Env-
mediated fusion are present in human macrophages, we
tested three SIVmac Envs that have well-characterized
coreceptor usage profiles (Broder and Jones-Trower,
1999). A cell–cell fusion assay was used that employs
effector cells infected with Env-expressing recombinant
vaccinia viruses and primary monocyte-derived macro-
phages (MDM) as targets. Since SIV uses CCR5 as its
primary coreceptor, we tested MDM lacking CCR5 ob-
tained from individuals homozygous for the non-func-
tional CCR5 D32 deletion allele (Rana et al., 1997) along
with wild-type MDM. In addition to SIVmac239, SIV-
mac251, and SIVmac316, we tested Envs from the R5
HIV-1 strain JRFL, which is restricted to CCR5 on human
MDM, and the R5X4 HIV-1 strain 89.6, which uses both
CCR5 and CXCR4 on macrophages (Yi et al., 1998).
As shown in Fig. 1A, all three SIVmac Envs efficiently
fused with wild-type macrophages as expected since SIV
uses human CCR5 as coreceptor. SIVmac316 Env also
fused with macrophages lacking CCR5, indicating an-
other pathway in addition to CCR5. In contrast, SIV-
mac239 and -251 failed to fuse with macrophages lack-
ing CCR5, indicating that these Envs were restricted to
CCR5 in human macrophages. CCR5-independent fusion
by SIVmac316 was relatively robust as luciferase levels
in CCR5-negative MDM from different D32 homozygous
donors were typically ;50% of that in wild-type MDM
tested in parallel. Both 89.6 and JRFL also fused with
wild-type macrophages. JRFL was completely blocked in
MDM lacking CCR5, but 89.6 was able to fuse, consistentwith its ability to use both CCR5 and CXCR4 on macro-
phages. Thus, human macrophages possess a fusion
pathway independent of CCR5 that can be used selec-
tively by SIVmac316 but not by SIVmac239 or SIVmac251.
CXCR4 is not responsible for CCR5-independent
SIVmac macrophage fusion
While SIV generally does not use CXCR4, some excep-
tions exist (Owen et al., 2000). Since human macro-
phages express CXCR4, which supports CCR5-indepen-
dent entry by certain HIV-1 strains (Simmons et al., 1998;
Yi et al., 1999), we determined whether CXCR4 might be
responsible for SIVmac316 MDM fusion independent of
CCR5 (Fig. 1B). CCR5-negative MDM were used as tar-
gets, and CXCR4 was blocked by the specific antagonist
AMD3100 (Schols et al., 1997). When HIV-1 89.6 Env was
expressed in effector cells, blocking CXCR4 abrogated
fusion, consistent with CCR5 and CXCR4 as the only
functional macrophage coreceptors for 89.6. In contrast,
AMD3100 had no effect on CCR5-independent SIV-
mac316 fusion, suggesting that the non-CCR5 pathway in
human macrophages for SIVmac316 does not involve
CXCR4. Although AMD3100 may inhibit CXCR4 utilization
by SIV less efficiently than by HIV-1 (Owen et al., 2000),
the lack of any effect is concordant with the well-estab-
lished observation that SIVmac316 does not fuse with
CXCR4 in transfection-based systems (Rucker et al.,
1997; Kirchhoff et al., 1997; Alkhatib et al., 1997).
CD4 dependence of SIVmac fusion with human
macrophages
Many SIV strains use CCR5 independent of CD4
(Edinger et al., 1997; Martin et al., 1997), but the second-
ary coreceptors identified so far all function only in con-
junction with CD4. Therefore, we next determined
whether CCR5-independent fusion with human macro-
phages required CD4 as would be expected for a path-
way that functions as a coreceptor. Macrophages were
treated with Leu3a, a CD4-blocking mAb, prior to and
during mixing with Env-expressing effector cells. Since
we tested both wild-type and CCR5-deficient MDM, this
also enabled us to determine whether SIV fusion with
primary macrophages mediated by CCR5 could occur
independent of CD4.
For HIV-1 89.6, fusion with both wild-type and CCR5-
negative MDM was blocked by the CD4 mAb (Fig. 2) as
expected since 89.6 Env utilization of both CCR5 and
CXCR4 is CD4 dependent. In contrast, fusion mediated
by SIVmac316 Env with wild-type MDM was only partially
inhibited by CD4 mAb. Higher concentrations of antibody
did not further increase the level of blocking (data not
shown), indicating that the apparent CD4-independent
fusion was not a consequence of inadequate blocking.
While there was considerable donor-to-donor variability
in the proportion of fusion resistant to CD4 blocking,
n level
144 YI ET AL.ranging from 10 to 70% among different wild-type MDM
donors, the level of luciferase expression in the pres-
ence of CD4 inhibition averaged about one-third of that
without blocking. In CCR5-negative macrophages, how-
ever, SIVmac316 Env was efficiently inhibited by CD4
blocking (Fig. 2). Since fusion with CCR5-negative MDM
requires CD4, this result confirms that this pathway func-
tions as a coreceptor and does not reflect some funda-
mentally distinct mechanism of entry. Because CD4-in-
dependent fusion occurred only in CCR5-expressing
MDM, these data also indicate that CCR5 is responsible
for CD4-independent macrophage fusion. Thus, macro-
phages have two fusion pathways for SIVmac316: a
CCR5-mediated pathway that is partially CD4 indepen-
FIG. 1. CCR5-independent fusion with primary macrophages media
transfected with a T7-driven luciferase plasmid and infected with recom
strains JRFL and 89.6, and a mutant HIV-1 Env lacking the gp120/gp
macrophages (MDM) from donors homozygous for the wild-type (W/W) o
a recombinant vaccinia virus expressing the T7 polymerase. Luciferase
fusion. Data represent the means 6 SE of four independent experim
macrophage fusion. CCR5-negative target macrophages were treated w
with effector cells expressing Env from SIVmac316 or HIV-1 89.6. Fusio
agent and are the means 6 SE of three independent experiments.dent and a CCR5-independent pathway that is CD4 de-
pendent. These results also confirm and extend to thecontext of primary macrophages previous observations
both that SIV can utilize CCR5 independently of CD4 and
that the secondary coreceptors only function in conjunc-
tion with CD4.
Secondary coreceptor pathways in MDM do not
support SIVmac316 pseudotype infection
Since these results demonstrated both CCR5-medi-
ated and alternative coreceptor-mediated SIV fusion in
human macrophages, we next tested whether both path-
ways were also capable of mediating infection. Using
infectious virus stocks of SIVmac239, -251, and -316, we
found that none of the SIV strains established productive
SIVmac Env. (A) Cell–cell fusion was tested using effector 293T cells
vaccinia viruses expressing Env from three SIVmac strains, the HIV-1
avage site. Env-expressing cells were mixed with monocyte-derived
unctional CCR5 D32 deletion allele (D/D), which had been infected with
was measured in cell lysates 6 h later as an indication of Env-mediated
ing different MDM donors. (B) Role of CXCR4 in CCR5-independent
ithout the CXCR4-specific inhibitor AMD3100 (10 mg/ml) prior to mixing
s are shown as a percentage of that seen in the absence of blockingted by
binant
41 cle
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ith or wreplication in human macrophages regardless of
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145ALTERNATIVE SIV CORECEPTORS ON HUMAN MACROPHAGESsimilar to a previous report of SIV restriction in human
macrophages (Chen et al., 1998). Therefore, to overcome
potential restrictions linked to viral genes other than env,
we employed pseudotype virions containing the HIV-1
core and SIVmac316 Env. As controls we used
pseudotypes incorporating Env from the R5 HIV-1 strain
ADA and Env from the amphitropic murine leukemia virus
(MLV), which is independent of CD4 and coreceptors.
Pseudotype viruses were used to infect CCR5-deficient
and wild-type MDM as well as CEMX174 cells, which do
not express CCR5 but are permissive for SIV on the basis
FIG. 2. CD4-independent Env-mediated fusion with macrophages. Effe
ild-type and CCR5-deficient MDM that were pre-treated with or witho
a percentage of that seen in the absence of blocking, and represent t
FIG. 3. Infection of primary macrophages by luciferase reporter
macrophages (D/D), and CEMX174 cells were infected with pseudotype
the basis of p24 antigen content. Cells were lysed 3 days later and analyzed
ndependent experiments.of alternative coreceptor expression (Farzan et al., 1997;
irchhoff et al., 1997).
As expected, ADA pseudotypes infected wild-type
DM but not CCR5-deficient MDM or CEMX174 cells,
hile MLV pseudotypes infected all three target cells
Fig. 3). SIVmac316 pseudotypes also infected wild-type
acrophages and CEMX174 cells. However, in marked
ontrast to fusion results, SIVmac316 pseudotype virions
ailed to infect CCR5-negative macrophages from three
ifferent donors tested. Thus, the CCR5-independent
acrophage pathway mediates SIVmac316 fusion but
lls expressing HIV-1 89.6 or SIVmac316 Envs were allowed to fuse with
CD4-blocking mAb Leu3a (10 mg/ml). Fusion levels are expressed as
ns 6 SE of three independent experiments.
pseudotype virions. Wild-type macrophages (W/W), CCR5-deficient
ing Env from SIVmac316, HIV-1 ADA, or MLV, which were equalized onctor cegene
s carryfor luciferase expression. The data show the means 6 SE of three
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146 YI ET AL.does not support infection, while CCR5 supports both
fusion and infection. These results also indicate a dis-
tinction in macrophages between functions needed for
fusion and infection that is coreceptor specific.
Analysis of chemokine receptor message in human
macrophages
To address potential coreceptor pathways involved in
macrophage fusion independent of CCR5, we compared
the coreceptors known to be used by SIVmac239, -251,
and -316 (Broder and Jones-Trower, 1999). Although sub-
tle differences in coreceptor patterns can result from
different assay systems, all three isolates are consis-
tently reported to use STRL33, GPR1, and GPR15, two of
the three strains use APJ and ChemR23, and CCR8 is
used mainly by SIVmac316. Therefore, we focused on
these molecules as coreceptors that might be responsi-
ble for CCR5-independent macrophage fusion by SIV-
mac316 (Table 1). By RT–PCR we detected expression of
CXCR4 and b-actin in macrophage cultures (Fig. 4A), as
well as CD4 and CCR5 (data not shown). We confirmed
that the signal represented RNA, rather than DNA con-
tamination, by the absence of products when samples
were treated with RNase A and the reverse transcription
step was omitted and by the size of the b-actin amplicon,
hich distinguishes between DNA and RNA (Table 1). In
ells from multiple donors, we obtained no signal for
T
PCR Primers Used for Detection of
Target Forward primer
CXCR4
1st Round 59-GAACTTCCTATGCAAGGCAGTCC-39
GPR1
1st Round 59-TTGGCGGTCCTGCCCTGTACTT-39
Nested 59-AGAAGCATGATCCTGACCTCAC-39
GPR15
1st Round 59-CTGGTTTATCTCCTGCCTGCTGGG-39
Nested 59-GCTCACGCTGATTGATGATAAG-39
STRL33
1st Round 59-CCAGGAGGAGCATCAAGACTTCC-39
Nested 59-AAGGTCTTTCTGCCCTGCATGT-39
APJ
1st Round 59-TACACAGACTGGAAATCCTCG-39
Nested 59-CCCTCATCCCTGCCATCTACAT-39
ChemR23
1st Round 59-GGGATTCTGGGAATGGT-39
Nested 59-AACCTGGCAGTGGCAGATTTC-39
CCR8
1st Round 59-TCCATGCCGTGTATGCCC-39
Nested 59-TGAGGACGATCAGGATGGGCA-39
b-Actin
1st Round 59-GCACCACACCTTCTACATGAG-39CR8, GPR1, GPR15, STRL33, ChemR23, or APJ. Since
hese primers can detect 100 (CCR8, APJ, GPR1,
d
shemR23, CXCR4) to 10,000 (GPR15 and STRL33) copies
f target based on serial dilutions of plasmid DNA (data
ot shown), this result suggests that none of these co-
eceptors are significantly expressed in human macro-
hages. We then carried out nested PCR (Fig. 4B) using
nternal primer sets that increase the sensitivity ;100-
old (data not shown). By nested PCR, a signal was
etected for CCR8, GPR1, GPR15, STRL33, ChemR23,
nd APJ. Taken together, these results suggest that these
oreceptors are expressed at the level of RNA expres-
ion in MDM but at extremely low levels that are below
he threshold of sensitivity for standard RT–PCR.
DISCUSSION
Multiple coreceptors in addition to CCR5 and CXCR4
an support immunodeficiency virus entry in transfected
ells in vitro, but whether they are pertinent to AIDS
athogenesis depends upon whether alternative core-
eptors (i) are actually used for HIV-1 infection of target
ells in vivo, perhaps in specialized tissue compart-
ents, or (ii) are expressed on relevant primary human
arget cells in a form functional for entry, such that they
ould provide a potential infection pathway for HIV-1
ariants that might emerge in the face of therapeutic
fforts to block CCR5 and CXCR4. Our study demon-
trates that human macrophages express a coreceptor
ther than CCR5 and CXCR4 that supports CD4-depen-
eptor Expression in Macrophages
Reverse primer Product (bp)
59-CCATGATGTGCTGAAACTGGAAC-39 304
59-GGAAGCGAGCTTGGAACTTCTT-39 444
59-TGGGGTTCAAGCAACTATTGAG-39 330
59-GGCAGCCAGGAGACAAGAAAGGC-39 297
59-TTTCCTGATTGCTGGTAATGGG-39 174
59-AGGTCATCCTGTTGGCTTGCTGG-39 383
59-GGTGGCCTTAACCACTACAATG-39 315
59-TGCACCTTAGTGGTGTTCTCC-39 479
59-CATTGGCCACTGGCCTCACGAT-39 327
59-GGGCACCAGCAGAGGAAG-39 665
59-AGACGAGAGATGGGGAACTCAAG-39 292
59-CCACGTTGAATGGGACCC-39 363
59-ACCAACCTGATGGCCTTGGTCT-39 289
59-ATAGCACAGCCTGGATAGCAAC-39 164 (RNA)
605 (DNA)ABLE 1
Corecent SIV Env fusion. This is the first report to demon-
trate alternative entry coreceptor function in human
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147ALTERNATIVE SIV CORECEPTORS ON HUMAN MACROPHAGESmacrophages, an important target cell in vivo. However,
the alternative pathway did not enable macrophage in-
fection despite efficient fusion, even when all viral genes
other than env were derived from HIV-1. Thus, even in the
ace of fusion-competent Envs, entry pathways other
han CCR5 and CXCR4 may be intrinsically unable to
ediate infection of primary macrophages.
A strong argument against a role for alternative entry
oreceptors in vivo at present is the fact that most HIV-1
trains cannot replicate in primary human cells in the
bsence of functional CCR5 and CXCR4 (Rana et al.,
997; Simmons et al., 1998; Zhang and Moore, 1999).
lso, secondary coreceptor use by naturally occurring
IV-1 isolates is highly variable and usually inefficient
albeit with some exceptions (Zhang and Moore, 1999)],
uggesting that it is not a selectively advantaged pheno-
ype in vivo. Furthermore, while alternative coreceptors
ight function in specific tissue compartments in vivo,
everal groups including ours have been unable to show
clear association between alternative coreceptor us-
ge patterns and organ compartmentalization (Singh et
l., 1999; Chan et al., 1999). On the other hand, CCR5/
XCR4-independent infection of human PBL has been
escribed for a single HIV-1 isolate that uses STRL33
Sharron et al., 2000); CCR3 is used by a relatively broad
ange of HIV-1 isolates and has been proposed as an
ntry pathway in the central nervous system (He et al.,
FIG. 4. RT–PCR detection of coreceptor expression in human macrop
to reverse transcription followed by nested PCR amplification. RNA
following RNase treatment and omission of the RT incubation step (2)
agarose gel electrophoresis and stained with ethidium bromide. (A)
amplification. Standards consisted of a 100-bp DNA ladder. Results ar997); CCR8 has been implicated as a coreceptor on
uman thymocytes (Lee et al., 2000); and GPR1 has been
beported to mediate entry into mesangial and brain-
erived cells (Shimizu et al., 1999; Tokizawa et al., 2000).
Regardless of any role for alternative coreceptor path-
ays at present, a critical question is whether they could
ecome important if the primary coreceptors were
locked, given that CCR5 and CXCR4 entry antagonists
re the focus of intensive development (D’Souza et al.,
000). Coreceptor function requires more than just ex-
ression in conjunction with CD4, and evidence for fu-
ion, entry, or infection is critical in assessing the impor-
ance of potential pathways. However, this may be diffi-
ult to examine with HIV-1, since naturally occurring
solates generally use the secondary coreceptors poorly.
n contrast, SIV uses alternative coreceptors very well.
herefore, even though human cells are not natural tar-
ets for SIV infection, SIV Envs can serve as a probe into
lternative entry pathways present on human cells. Re-
ent studies using human PBL have implicated alterna-
ive pathways for entry by some SIV strains (Chen et al.,
997; Sharron et al., 2000; Zhang et al., 2000), but alter-
ative coreceptor pathways in macrophages have not
een examined. Our study demonstrates that macro-
hages do express alternative fusion coreceptor func-
ion, but the inability of this pathway to support infection
ven when a fusion-competent Env is pseudotyped with
n HIV-1 core suggests that secondary coreceptors may
ot offer a route of viral escape after principal coreceptor
Total RNA was extracted from 7-day-old MDM cultures and subjected
plified following reverse transcription (1) or, as a negative control,
id DNA served as a positive control (“c”). Products were separated by
the first round PCR products, and (B) shows the results of nested
sentative of three experiments using different cell donors.hages.
was am
. Plasmlockade.
The dichotomy between fusion and infection mediated
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148 YI ET AL.by this pathway is clearly linked to interactions between
Env and the coreceptor since SIVmac316 Env
pseudotypes infected MDM if CCR5 was present and
MLV pseudotypes infected both CCR5-deficient and wild-
type MDM. However, the reason that this pathway sup-
ports fusion but not infection is uncertain. One possibility
is that the coreceptor might be expressed on macro-
phages at a relatively low level that is adequate to
support cell–cell fusion by Env overexpressed on the
surface of a transfected cell but insufficient to support
fusion (and therefore infection) by Env expressed on a
virion surface. It is also possible that virion Env may have
a slightly different conformation from cell-expressed Env,
which renders it unable to interact with this coreceptor.
Alternatively, it is increasingly evident that interactions in
addition to fusion are required for infection under some
circumstances (Chackerian et al., 1997), which suggests
hat the alternative coreceptor might lack such postfu-
ion functions that enable permissive entry through the
rincipal coreceptors. Along these lines, Env binding
licits intracellular signals through CCR5 and CXCR4 in
oth macrophages and PBL (Liu et al., 2000; Weissman
t al., 1997), and while coreceptor signaling is dispens-
ble for infection in cell lines, these signals were re-
ently implicated in regulating productive or non-produc-
ive macrophage entry (Arthos et al., 2000). We therefore
ypothesized that the alternative coreceptor might lack
uch signals and tested whether chemokine-induced
ignaling would enable macrophage infection to proceed
hrough the alternative pathway. However, we found no
nhancement of infection when CCR5-deficient MDM
ere treated with chemokines prior to, during, or after
nfection by SIVmac316 pseudotypes (data not shown).
hus, the reason that this pathway fails to allow infection
espite efficient fusion remains to be determined.
The CCR5/CXCR4-independent macrophage pathway
equired CD4 for fusion, which indicates that it functions
s a typical coreceptor rather than representing some
undamentally distinct entry mechanism completely in-
ependent of CD4. The identity of this alternative core-
eptor, however, is unclear. None of the likely secondary
oreceptor candidates were detected by single-round
T–PCR, which suggests that they are not highly ex-
ressed in macrophages. Comparing the patterns of
oreceptor utilization by the strains tested also failed to
dentify a clear candidate. CCR8 is used by SIVmac316
nd not by the other SIV strains (Broder and Jones-
rower, 1999). However HIV-1 89.6 also uses CCR8 in
ransfection-based systems, yet 89.6 does not fuse with
DM independent of CCR5 and CXCR4 (Fig. 2 and data
ot shown). STRL33 has been implicated as a pathway
or entry independent of CCR5 and CXCR4 in human PBL
Sharron et al., 2000), but all three SIVmac strains tested
an use STRL33 while only 316 fused with CCR5-defi-
ient MDM. None of the other established alternative
oreceptors are used selectively by SIVmac316 (Brodernd Jones-Trower, 1999). Thus, it is uncertain whether
ow-level expression of one of these receptors is able to
ediate SIVmac316 fusion in a strain-specific manner or
hether some yet undefined molecule is responsible.
We found that SIVmac316 was capable of utilizing
CR5 on primary macrophages independently of CD4.
his result is concordant with CD4 independent use of
CR5 by some SIV strains in transfection-based systems
nd certain other cells (Martin et al., 1997; Edinger et al.,
997). Recently, Mori et al. suggested that SIVmac316
acrophage tropism was linked to an ability to infect
hesus alveolar macrophages despite low or absent lev-
ls of CD4 (Mori et al., 2000). Our results are consistent
ith this notion and extend to the level of Env-mediated
embrane fusion the observation that SIVmac316 can
se CCR5 on macrophages independent of CD4.
In summary, using SIVmac Env as a probe to examine
oreceptor pathways for fusion and infection on primary
uman macrophages, we show that macrophages pos-
ess an alternative fusion coreceptor pathway indepen-
ent of CCR5 and CXCR4 that can be used by SIV. This is
he first report of an additional coreceptor pathway on
rimary human macrophages. However, in contrast to
usion, the alternative pathway does not mediate infec-
ion even if SIV Env is pseudotyped with an HIV-1 core.
his indicates that alternative coreceptors may lack the
bility to mediate macrophage infection even for variants
hat use them efficiently for fusion and offers reason for
ptimism regarding efforts to develop therapies that in-
ibit HIV-1 replication through principal entry coreceptor
lockade.
MATERIALS AND METHODS
solation of monocyte-derived macrophages
Peripheral blood mononuclear cells were isolated by
icoll–Hypaque from blood of normal volunteers, and
onocytes were purified by two-step adherence selec-
ion and cultured as previously described (Collman et al.,
989). Cells were plated at 2 3 105 cells per well in
8-well plates, maintained in DMEM supplemented with
0% fetal bovine serum, 10% horse serum, glutamine (1
M), penicillin (100 U/ml), streptomycin (100 mg/ml), and
-CSF (100 U/ml; Genetics Institute, Cambridge, MA),
nd cultured for 1 week before use to allow differentia-
ion into monocyte-derived macrophages (MDM). Blood
onors were screened for the CCR5 D32 deletion allele
y PCR as previously described (Rana et al., 1997), and
cells from donors homozygous for the CCR5 wild-type or
nonfunctional D32 alleles were used. At least four differ-
ent donors of each genotype were used for these stud-
ies.
Cell–cell fusion with primary macrophagesEnv glycoproteins expressed by recombinant vaccinia
viruses were analyzed for fusion with primary MDM
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149ALTERNATIVE SIV CORECEPTORS ON HUMAN MACROPHAGEStarget cells using a cell–cell fusion assay (Broder and
Berger, 1995; Yi et al., 1999). Effector 293T cells were
nfected with Env-expressing recombinant vaccinia virus
or 1 h at an m.o.i. of 10, transfected using FuGENE6
Roche Molecular Biochemicals, Indianapolis, IN) with a
lasmid encoding the luciferase reporter gene under the
ontrol of T7 promoter, and then incubated at 32°C
vernight with rifampicin (0.1 mg/ml). Macrophages were
nfected for 1 h at an m.o.i. of 5 with recombinant vaccinia
irus vTF7.3, which expresses the T7 polymerase, and
hen incubated overnight at 32°C with rifampicin. Effec-
or 293T cells were then mixed with macrophages in the
resence of rifampicin and ara-C (0.1 mM), and luciferase
activity was measured in cell lysates 6 h later. The
recombinant vaccinia viruses expressing Env from SIV-
mac316 (vCB75), SIVmac251 (v194), SIVmac239 (vCB74),
HIV-1 89.6 (vBD3), and HIV-1 JRFL (vCB28) were provided
by R. Doms (University of Pennsylvania). To block fusion,
the anti-CD4 mAb Leu3a (10 mg/ml; Becton-Dickinson,
ranklin Lakes, NJ) or CXCR4 antagonist AMD3100 (10
mg/ml; provided by J. Strizki, Schering-Plough Research
Institute, Kenilworth, NJ) was added to target MDM 1 h
prior to the addition of effector cells.
Pseudotype infections
Single-cycle reporter virions were prepared by co-
transfecting 293T cells by FuGENE6 with plasmids en-
coding env from SIV, HIV-1, or murine leukemia virus
(MLV) and the env-defective HIV-1 luciferase reporter
virus backbone pNL-Luc-E2R1 (provided by N. Landau,
alk Institute, La Jolla, CA) in the presence of sodium
utyrate (7.5 mM). Supernatant was collected 48 h later
nd HIV-1 p24 Gag antigen content measured by ELISA
ZeptoMetrix Corp., Buffalo, NY). Cells were infected with
seudotype viruses using 20 ng p24 antigen per virus in
he presence of Polybrene (7.5 mg/ml), and lysed 3 days
later for measurement of luciferase activity.
Reverse transcription (RT)–PCR
Total RNA was isolated from 4 3 106 MDM after 1
week in culture using Trizol reagent (Gibco-BRL, Rock-
ville, MD). RNA was treated for 30 min at 37°C with 30 U
of DNase I in the presence of 5 mM MgCl2, which was
then inactivated by heating to 65°C for 15 min and 5 mM
EDTA. rTth polymerase was used for both RT and PCR
steps with conditions as recommended by the manufac-
turer (EZ rTth RNA PCR kit; Perkin–Elmer, Norwalk, CT).
Reverse transcription was carried out using the reverse
primer for 30 min at 61°C, followed by PCR amplification
(94°C for 2.5 min followed by 30 cycles of 94°C for 30 s,
57°C for 30 s, and 61°C 1 min). Products of the first round
(1 ml) were then subjected to a second round of ampli-
ication using Taq polymerase (Perkin–Elmer) and nested
rimers under the same conditions. Primer pairs andmplification product sizes are shown in Table 1. As a
ontrol to ensure that RNA and not DNA contamination
as being detected, PCR was carried out on RNA that
as treated for 30 min with 1 ml of RNase A in the
presence of 5 mM MgCl2 and from which the RT incu-
bation step was omitted. As another control, RT-PCR was
carried out for b-actin using primers, shown in Table 1,
hat yield a product of 164 bp from RNA and 605 bp from
NA. Amplification products were separated by gel elec-
rophoresis in 2% agarose and stained with ethidium
romide. PCR sensitivity was tested using serial dilution
f coreceptor plasmid.
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